- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT02153489
A Double-blind, Placebo-controlled, Crossover Study to Assess the Effect of Aclidinium Bromide 400 μg Bid on COPD Symptoms and Sleep Quality After 3 Weeks of Treatment in Patients With Stable Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)
20 września 2016 zaktualizowane przez: AstraZeneca
A Pilot, Double-blind, Placebo-controlled, 2-period Crossover Study to Assess the Effect of Aclidinium Bromide 400 μg Bid on COPD Symptoms and Sleep Quality After 3 Weeks of Treatment in Patients With Stable Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this study is to assess the effect of aclidinium bromide compared with placebo in improving dilatation of the airways (bronchodilation), symptoms of chronic obstructive pulmonary disease (COPD), sleep quality and physical activity after 3 weeks of treatment with aclidinium bromide 400 μg administered twice daily in patients with stable moderate-and-severe COPD.
Przegląd badań
Status
Zakończony
Interwencja / Leczenie
Typ studiów
Interwencyjne
Zapisy (Rzeczywisty)
30
Faza
- Faza 4
Kontakty i lokalizacje
Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.
Lokalizacje studiów
-
-
-
Grosshansdorf, Niemcy, 22927
- Pulmonary Research Institute at the Lung Clinic Grosshansdorf
-
Immenhausen, Niemcy, 34376
- Pneumologische Lehrklinik der Universitätsmedizin Göttingen
-
-
Kryteria uczestnictwa
Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.
Kryteria kwalifikacji
Wiek uprawniający do nauki
40 lat i starsze (Dorosły, Starszy dorosły)
Akceptuje zdrowych ochotników
Nie
Płeć kwalifikująca się do nauki
Wszystko
Opis
Inclusion Criteria:
- Adult male or non-pregnant, non-lactating female aged ≥40 years. Women of childbearing potential will follow specific study requirements (negative serum pregnancy test at the Screening Visit and are using, over the last two months before the Screening Visit, at least one medically approved and highly effective method of birth control
- Current or ex-cigarette smoker (patients who quit smoking more than 6 months prior to the Screening Visit), with a smoking history of at least 10 pack-years.
- Patients with a clinical diagnosis of chronic obstructive pulmonary disease (COPD) according to GOLD guidelines 2013, with a post bronchodilator FEV1 <80%, and FEV1 ≥ 40% at Screening Visit
- Patients must be able to perform repeatable pulmonary function testing for FEV1 according to American Thoracic Society [ATS]/European Respiratory Society [ERS] 2005 criteria at Screening Visit
- Patients who are eligible and able to participate in the study and who consents to do so in writing after the purpose and nature of the investigation have been explained
Exclusion Criteria:
- History or current diagnosis of asthma
- Patients with moderate to severe sleep apnoea assessed at screening
- Patients who develop a respiratory tract infection or COPD exacerbation within 6 weeks (or 3 months if hospitalisation was required) before the Screening Visit (Visit 1) or during the run-in period
- Clinically significant respiratory conditions
- Patients with Type I or uncontrolled Type II diabetes, uncontrolled hypo-or hyperthyroidism, hypokalaemia, or hyperadrenergic state, uncontrolled or untreated hypertension
- Patients who may need to start a pulmonary rehabilitation program during the study and/or patients who started/finished it within 3 months prior to the Screening Visit
- Use of long-term oxygen therapy (15 hours/day)
- Patients who does not maintain regular day/night, waking/sleeping cycles including night shift workers
- Clinically significant cardiovascular conditions
- QTc >470 milliseconds in the manual ECG reading performed at Screening Visit
- Patients with clinically relevant abnormalities in the opinion of the investigator at the Screening Visit (Visit 1) in the results of the clinical laboratory tests, ECG parameters or in the physical examination)
- Patients with a history of hypersensitivity reaction to inhaled anticholinergics, long and short acting β2-agonists, sympathomimetic amines, or inhaled medication or any component there of (including report of paradoxical bronchospasm)
- Patients with known narrow-angle glaucoma, symptomatic bladder neck obstruction, acute urinary retention, or patients with symptomatic non-stable prostatic hypertrophy
- Patients with known non-controlled history of human immunodeficiency virus (HIV) infection and/or active hepatitis
- History of malignancy of any organ system (including lung cancer), treated or untreated, within the past 5 years other than basal or squamous cell skin cancer
- Patients with any other serious or uncontrolled physical or mental dysfunction, or moderate-to-severe depression, as confirmed by Beck Depression Inventory (BDI-II) total score >28.
- Patients with a history (within 2 years prior to the Screening Visit) of drug and/or alcohol abuse that may prevent study compliance based on investigator judgment
- Patients unlikely to be cooperative or that can't comply with the study procedures.
- Patients treated with any investigational drug within 30 days (or 6 half-lives, whichever is longer) prior to the Screening Visit
- Patients who intends to use any concomitant medication not permitted by this protocol or who have not undergone the required stabilization periods for prohibited medication
- Any other conditions that, in the investigator's opinion, might indicate the patient to be unsuitable for the study
Plan studiów
Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie
- Przydział: Randomizowane
- Model interwencyjny: Zadanie krzyżowe
- Maskowanie: Poczwórny
Broń i interwencje
Grupa uczestników / Arm |
Interwencja / Leczenie |
---|---|
Eksperymentalny: Aclidinium bromide
Aclidinium bromide 400 μg administered via oral inhalation (Genuair® dry powder inhaler) one inhalation twice daily (12 hours apart, morning and evening).
|
Inne nazwy:
|
Komparator placebo: Placebo
Placebo administered via oral inhalation (Genuair® dry powder inhaler) one inhalation twice daily (12 hours apart, morning and evening).
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Ramy czasowe |
---|---|
Change From Baseline in Normalized Forced Expiratory Volume in One Second (FEV1) AUC0-24hr
Ramy czasowe: 0, 0.5, 1, 2, 3, 4, 6, 8, 10, 11, 12, 12.5, 13, 14, 15, 16, 19, 22, 23, and 24 hours at Week 3 of treatment
|
0, 0.5, 1, 2, 3, 4, 6, 8, 10, 11, 12, 12.5, 13, 14, 15, 16, 19, 22, 23, and 24 hours at Week 3 of treatment
|
Inne miary wyników
Miara wyniku |
Opis środka |
Ramy czasowe |
---|---|---|
Change From Baseline in Morning Trough FEV1
Ramy czasowe: Week 3 of treatment
|
Week 3 of treatment
|
|
Change From Baseline in Peak FEV1
Ramy czasowe: Week 3 of treatment
|
Week 3 of treatment
|
|
Change From Baseline in Normalized FEV1 AUC0-12hr
Ramy czasowe: 0, 0.5, 1, 2, 3, 4, 6, 8, 10, 11 and 12 hours at Week 3 of treatment
|
0, 0.5, 1, 2, 3, 4, 6, 8, 10, 11 and 12 hours at Week 3 of treatment
|
|
Change From Baseline in Normalized FEV1 AUC12-24hr
Ramy czasowe: 12, 12.5, 13, 14, 15, 16, 19, 22, 23, and 24 hours at Week 3 of treatment
|
12, 12.5, 13, 14, 15, 16, 19, 22, 23, and 24 hours at Week 3 of treatment
|
|
Change From Baseline in the Average Rating of Overall Early Morning COPD Symptom Severity
Ramy czasowe: Week 3 of treatment
|
Night-time and early-morning symptoms were recorded every morning using the Early-Morning Symptoms of COPD Instrument [EMSCI] and the Night-time Symptoms of COPD Instrument [NiSCI].
Scores ranged from 0 (no symptoms) to 4 (very severe symptoms).
The questionnaires also evaluated nocturnal awakenings and limitation of early-morning activities (scores ranged from 0 [no limitation] to 4 [a very great deal]).
Symptoms assessed over 24 weeks included change from baseline in the severity of night-time and early-morning cough, wheezing, shortness of breath and difficulty bringing up phlegm, overall night-time and early-morning symptom severity, number of nocturnal awakenings and limitation of early-morning activities due to COPD symptoms
|
Week 3 of treatment
|
Change From Baseline in the Average Rating of Overall Evening COPD Symptom Severity
Ramy czasowe: Week 3 of treatment
|
The evening symptoms questionnaire was filled out after the second medication administration of the day and before bedtime.
Scores ranged from 0 (no symptoms) to 4 (very severe symptoms).
Symptoms assessed over 24 weeks included change from baseline in the severity of evening cough, wheezing, shortness of breath and tightness of the chest, chest congestion, difficulty bringing up phlegm, overall evening symptom severity, and limitation of evening activities due to COPD symptoms
|
Week 3 of treatment
|
Change From Baseline in the Average Rating of Overall Night-time COPD Symptom Severity
Ramy czasowe: Week 3 of treatment
|
Night-time and early-morning symptoms were recorded every morning using the Early-Morning Symptoms of COPD Instrument [EMSCI] and the Night-time Symptoms of COPD Instrument [NiSCI].
Scores ranged from 0 (no symptoms) to 4 (very severe symptoms).
The questionnaires also evaluated nocturnal awakenings and limitation of early-morning activities (scores ranged from 0 [no limitation] to 4 [a very great deal]).
Symptoms assessed over 24 weeks included change from baseline in the severity of night-time and early-morning cough, wheezing, shortness of breath and difficulty bringing up phlegm, overall night-time and early-morning symptom severity, number of nocturnal awakenings and limitation of early-morning activities due to COPD symptoms
|
Week 3 of treatment
|
Change From Baseline in the Average Rating of COPD Symptoms Limiting Early Morning Activities
Ramy czasowe: Week 3 of treatment
|
Night-time and early-morning symptoms were recorded every morning using the Early-Morning Symptoms of COPD Instrument [EMSCI] and the Night-time Symptoms of COPD Instrument [NiSCI].
Scores ranged from 0 (no symptoms) to 4 (very severe symptoms).
The questionnaires also evaluated nocturnal awakenings and limitation of early-morning activities (scores ranged from 0 [no limitation] to 4 [a very great deal]).
Symptoms assessed over 24 weeks included change from baseline in the severity of night-time and early-morning cough, wheezing, shortness of breath and difficulty bringing up phlegm, overall night-time and early-morning symptom severity, number of nocturnal awakenings and limitation of early-morning activities due to COPD symptoms
|
Week 3 of treatment
|
Change From Baseline in the Average Rating of COPD Symptoms Limiting Evening Activities
Ramy czasowe: Week 3 of treatment
|
The evening symptoms questionnaire was filled out after the second medication administration of the day and before bedtime.
Scores ranged from 0 (no symptoms) to 4 (very severe symptoms).
Symptoms assessed over 24 weeks included change from baseline in the severity of evening cough, wheezing, shortness of breath and tightness of the chest, chest congestion, difficulty bringing up phlegm, overall evening symptom severity, and limitation of evening activities due to COPD symptoms
|
Week 3 of treatment
|
Change From Baseline in Apnea-hypopnea Index (AHI) Per Hour of Total Sleep Time
Ramy czasowe: Week 3 of treatment
|
The Apnea Hypopnea Index (AHI) is used to indicate the severity of obstructive sleep apnea.
The AHI is the number of apneas or hypopneas recorded during the study per hour of sleep
|
Week 3 of treatment
|
Change From Baseline in Oxygen Desaturation Index (ODI) Per Hour of Total Sleep Time
Ramy czasowe: Week 3 of treatment
|
The oxygen desaturation index (ODI) is the number of times per hour of sleep that the blood's oxygen level drop by a certain degree from baseline.
In this study, any event with a 4% decrease in blood oxygen levels counted towards the total
|
Week 3 of treatment
|
Change From Baseline in Proportion of Sleep Stage REM as a Percentage of Total Sleep Time
Ramy czasowe: Week 3 of treatment
|
Week 3 of treatment
|
|
Change From Baseline in Sleep Efficiency
Ramy czasowe: Week 3 of treatment
|
Sleep efficiency is calculated as the total sleep time as a proportion of total time in bed
|
Week 3 of treatment
|
Change From Baseline in Total Sleep Time
Ramy czasowe: Week 3 of treatment
|
Week 3 of treatment
|
|
Change From Baseline in Duration of at Least Moderate Activity
Ramy czasowe: Week 3 of treatment
|
Moderate activity was defined as any physical activity >3 metabolic equivalents
|
Week 3 of treatment
|
Change From Baseline in Number of Steps Per Day
Ramy czasowe: Week 3 of treatment
|
Week 3 of treatment
|
Współpracownicy i badacze
Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.
Sponsor
Śledczy
- Dyrektor Studium: Anna Ribera, PhD, AstraZeneca Barcelona
Publikacje i pomocne linki
Osoba odpowiedzialna za wprowadzenie informacji o badaniu dobrowolnie udostępnia te publikacje. Mogą one dotyczyć wszystkiego, co jest związane z badaniem.
Daty zapisu na studia
Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.
Główne daty studiów
Rozpoczęcie studiów
1 kwietnia 2014
Zakończenie podstawowe (Rzeczywisty)
1 czerwca 2015
Ukończenie studiów (Rzeczywisty)
1 czerwca 2015
Daty rejestracji na studia
Pierwszy przesłany
5 maja 2014
Pierwszy przesłany, który spełnia kryteria kontroli jakości
30 maja 2014
Pierwszy wysłany (Oszacować)
3 czerwca 2014
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Oszacować)
9 listopada 2016
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
20 września 2016
Ostatnia weryfikacja
1 września 2016
Więcej informacji
Terminy związane z tym badaniem
Dodatkowe istotne warunki MeSH
Inne numery identyfikacyjne badania
- M/34273/47
- 2013-003373-10 (Numer EudraCT)
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .
Badania kliniczne na Przewlekła obturacyjna choroba płuc (POChP)
-
Spero TherapeuticsZakończonyKompleks Mycobacterium Avium | Niegruźlicze Mycobacterium Pulmonary DiseaseStany Zjednoczone
Badania kliniczne na Placebo
-
SamA Pharmaceutical Co., LtdNieznanyOstre zapalenie oskrzeli | Ostra infekcja górnych dróg oddechowychRepublika Korei
-
National Institute on Drug Abuse (NIDA)ZakończonyUżywanie konopi indyjskichStany Zjednoczone
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyZakończonyMężczyźni z cukrzycą typu II (T2DM)Niemcy
-
Heptares Therapeutics LimitedZakończonyFarmakokinetyka | Problemy z bezpieczeństwemZjednoczone Królestwo
-
West Penn Allegheny Health SystemZakończonyAstma | Alergiczny nieżyt nosaStany Zjednoczone
-
Soroka University Medical CenterZakończony
-
Regado Biosciences, Inc.ZakończonyZdrowy ochotnikStany Zjednoczone
-
Longeveron Inc.ZakończonyZespół niedorozwoju lewego sercaStany Zjednoczone
-
ItalfarmacoZakończonyDystrofia mięśniowa BeckeraHolandia, Włochy